Literature DB >> 31471331

Chemical Pathology of Homocysteine VII. Cholesterol, Thioretinaco Ozonide, Mitochondrial Dysfunction, and Prevention of Mortality.

Kilmer S McCully1.   

Abstract

The purpose of this review is to elucidate how low blood cholesterol promotes mitochondrial dysfunction and mortality by the loss of thioretinaco ozonide from opening of the mitochondrial permeability transition pore (mPTP). Mortality from infections and cancer are both inversely associated with blood cholesterol, as determined by multiple cohort studies from 10 to 30 years earlier. Moreover, low-density lipoprotein (LDL) is inversely related to all-cause and/or cardiovascular mortality, as determined by followup study of elderly cohorts. LDL adheres to and inactivates most microorganisms and their toxins, causing aggregation of LDL and homocysteinylated autoantibodies which obstruct vasa vasorum and produce intimal microabscesses, the vulnerable atherosclerotic plaques. The active site of mitochondrial oxidative phosphorylation and adenosine triphosphate (ATP) biosynthesis is proposed to consist of thioretinaco, a complex of two molecules of thioretinamide with cobalamin, oxidized to the disulfonium thioretinaco ozonide and complexed with oxygen, nicotinamide adenine dinucleotide (NAD+), phosphate, and ATP. Loss of the active site complex from mitochondria results from the opening of the mPTP and from decomposition of the disulfonium active site by electrophilic carcinogens, oncogenic viruses, microbes, and by reactive oxygen radicals from ionizing and non-ionizing radiation. Suppression of innate immunity is caused by the depletion of adenosyl methionine because of increased polyamine biosynthesis, resulting in inhibition of nitric oxide and peroxynitrite biosynthesis. Opening of the mPTP produces a loss of thioretinaco ozonide from mitochondria. This loss impairs ATP biosynthesis and causes the mitochondrial dysfunction observed in carcinogenesis, atherosclerosis, aging and dementia. Cholesterol inhibits the opening of the mPTP by preventing integration of the pro-apoptotic Bcl-2-associated X protein (BAX) in the outer mitochondrial membrane. This inhibition explains how elevated LDL reduces mitochondrial dysfunction by preventing loss of the active site of oxidative phosphorylation from mitochondria.
© 2019 by the Association of Clinical Scientists, Inc.

Entities:  

Keywords:  adenosyl methionine; aging; amyotrophic lateral sclerosis; apoptosis; cannabinoid; carcinogenesis; cholesterol; cystathionine synthase; deuterium; diallyl trisulfide; homocysteine; immunity; klotho; melatonin; mitochondrial dysfunction; mitochondrial membrane potential; mitochondrial permeability transition pore; myelodysplasia; napabucasin; nicotinamide adenine dinucleotide; nitric oxide; oxidative phosphorylation; ozone; pancreatic enzymes; peroxynitrite; singlet oxygen; statin; stem cells; tetrahydrobiopterin; thioretinaco ozonide; thioretinamide

Mesh:

Substances:

Year:  2019        PMID: 31471331

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  4 in total

1.  Transcutaneous Electrical Acupoint Stimulation Ameliorates Cognitive Function through PINK1/Parkin Mediated Mitophagy in VD Rats.

Authors:  Ziwei Hu; Tianshan Wen; Ke Hu; Rui Wang; Xinda Su; Wei Ouyang; Junjie Zhou; Youliang Wen
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-03       Impact factor: 2.650

2.  Commentary: Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential.

Authors:  Uffe Ravnskov; Kilmer S McCully
Journal:  Front Oncol       Date:  2022-05-02       Impact factor: 5.738

3.  Improvement of cognitive and motor performance with mitotherapy in aged mice.

Authors:  Zizhen Zhao; Zhenyao Yu; Yixue Hou; Le Zhang; Ailing Fu
Journal:  Int J Biol Sci       Date:  2020-01-16       Impact factor: 6.580

4.  Plasma Purification Treatment Relieves the Damage of Hyperlipidemia to PBMCs.

Authors:  Xiao Meng Zhang; Yan Hong Gu; Hao Deng; Zheng Quan Xu; Ze Yuan Zhong; Xia Jie Lyu; Hui Min Jin; Xiu Hong Yang
Journal:  Front Cardiovasc Med       Date:  2021-07-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.